PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Withdrawn before enrolling · Early Phase 1

Conditions studied: Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms

In brief

This is a single arm, phase 0 study to evaluate the safety and efficacy of PET-CT scans with FDG-labeled RBC in patients with breast cancer. Cardiac ejection fraction can be calculated and monitored in breast cancer patients during chemotherapy using a FDG-RBC PET-CT scan. The purpose of this study is to determine if calculated cardiac ejection fraction shows high concordance with results from echocardiography.

Key facts

Study ID

NCT03295695

Run by

H. Lee Moffitt Cancer Center and Research Institute

People needed

0

Starts

2020-12-01

Expected to finish

2022-12-01

Last updated by the study team

2020-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have histologically confirmed breast cancer and be scheduled for neoadjuvant Trastuzumab- or anthracycline-based chemotherapy.
• Age >18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky >60%).
• Must be able to complete an informed consent process.
• Must have normal organ and marrow function: leukocytes >3,000/μL; absolute neutrophil count >1,500/μL; platelets >100,000/μL; total bilirubin within normal institutional limits; aspartate aminotransferase (AST)[SGOT] / alanine aminotransferase (ALT)[SGPT]: less than 2.5 X institutional upper limit of normal; Creatinine within normal institutional limits - OR - creatinine clearance>60 mL/min/1.73 m\^2 for patients with creatinine level above institutional normal.
• Echocardiogram results should be of sufficiently suitable quality (adequate acoustic window access) to provide a reliable ejection fraction range calculation. The cardiac ejection fraction on the pre-treatment echocardiogram should be 50% or higher.
• Participants should be naïve to Trastuzumab or anthracycline chemotherapy prior to enrollment.

You may not qualify if…

• Prior history of invasive breast cancer and treatment with anthracycline chemotherapy.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDG.
• Known symptomatic coagulopathies, bleeding diathesis, hemoglobinopathies, or hemolytic anemia.
• Participants should have no clinically significant heart disease such as congestive heart failure. Participants should not have other significant structural heart disease by echocardiogram, or cardiac dysrhythmia on standard of care electrocardiogram that may adversely affect the cardiac imaging results obtained with FDG-RBC PET-CT imaging.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Women who are pregnant.
• Found to have a cardiac ejection fraction less than 50% on the pre-treatment echocardiogram.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.